Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

CTI BioPharma Corp Company Profile (NASDAQ:CTIC)

Consensus Ratings for CTI BioPharma Corp (NASDAQ:CTIC) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.75 (193.37% upside)

Analysts' Ratings History for CTI BioPharma Corp (NASDAQ:CTIC)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/23/2015Roth CapitalSet Price TargetBuy$4.50ViewTweet This Rating  Share This Rating on StockTwits
3/9/2015Piper JaffraySet Price Target$6.00 -> $8.00ViewTweet This Rating  Share This Rating on StockTwits
9/8/2014Piper JaffrayInitiated CoverageOverweight$6.00ViewTweet This Rating  Share This Rating on StockTwits
8/5/2014WallachBeth CapitalUpgradeHold -> Buy$4.50ViewTweet This Rating  Share This Rating on StockTwits
5/22/2014Ladenburg ThalmannInitiated CoverageBuy$6.00ViewTweet This Rating  Share This Rating on StockTwits
3/19/2014WallachBeth CapitalInitiated CoverageHold$4.50ViewTweet This Rating  Share This Rating on StockTwits
11/4/2013HC WainrightInitiated CoverageBuy$4.00ViewTweet This Rating  Share This Rating on StockTwits
10/29/2013Janney Montgomery ScottInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
10/7/2013Wells Fargo & Co.Reiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/26/2013 forward)